StockNews.AI
NRXP
StockNews.AI
105 days

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

1. HOPE Therapeutics will host an investor event on May 8, 2025. 2. Key topics include HOPE's clinic expansions and pipeline progress. 3. NRX-100's NDA status is aided by a $4.3 million FDA fee waiver. 4. Potential patent for NRX-100 could ensure market exclusivity until 2045. 5. Breakthrough Therapy Designation for NRX-101 supports pending NDA for bipolar depression.

10m saved
Insight
Article

FAQ

Why Bullish?

The positive developments around NRX-100 and NRX-101 indicate strong future growth potential, similar to past breakthroughs in the biotech sector that led to significant stock price increases.

How important is it?

The article discusses major advancements and regulatory milestones that are crucial for NRXP's future, promoting investor confidence.

Why Long Term?

As clinical trials and approvals mature, the potential for revenue generation will be realized, impacting the share price positively over the coming years.

Related Companies

KETNPTSDSPACE
, /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that it will host an investor event at the Mar-A-Lago Club in Palm Beach, Florida, on Thursday, May 8, 2025, at the invitation of club members. HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.) This discussion is being held to review previously-disclosed strategic initiatives across HOPE and NRx Pharmaceuticals, including expansion plans for the HOPE network of interventional psychiatry clinics and progress across the NRx clinical pipeline. Current investors who wish to attend are invited to contact the Company. Key Topics to be Discussed, based on previously disclosed information: Recently announced HOPE clinic acquisitions and potential to scale HOPE's interventional psychiatry network Plans for integration of digital health solutions, including CRM-based technology and telepsychiatry capabilities, to unify clinical operations across the HOPE network Status of the New Drug Application (NDA) for NRX-100 (preservative-free IV Ketamine), following FDA's grant of a $4.3 million filing fee waiver, for treating suicidal depression Recent filing of a patent for preservative-free ketamine (NRX-100).  If granted, the patent could provide market exclusivity for NRX-100 into 2045 Breakthrough Therapy Designation of NRX-101; currently preparing to file an NDA for Accelerated Approval in patients with bipolar depression and suicidality or akathisia Dr. Jonathan Javitt, MD, MPH, Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics will lead the discussion."We are excited to continue to meet with our investor community to discuss the significant progress we've made recently," said Dr. Javitt. "Our continued focus on expanding access to innovative treatments and delivering on key regulatory and operational milestones underscores the potential of HOPE and NRx's leadership in mental health innovation."About NRx Pharmaceuticals, Inc.NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.About HOPE Therapeutics, Inc.HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetic stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics.  More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy    Brian Korb Co-CEO, Hope Therapeutics, Inc.  Managing Partner, astr partners Chief Business Officer, NRx Pharmaceuticals, Inc. (917) 653-5122 [email protected]     [email protected] SOURCE NRx Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News